Recurrent CMV Retinitis in a Daratumumab-Treated Multiple Myeloma Patient With Systemic Antiviral Intolerance

Key Points

• This case aims to underline the risk of CMV retinitis in patients receiving daratumumab when systemic antiviral treatment is not tolerated.
• Describes the clinical course of a patient with multiple myeloma treated with daratumumab
• Discusses the management strategies employed due to antiviral intolerance
• Emphasizes the role of ophthalmologic monitoring
• Patient experienced recurrent episodes of CMV retinitis despite daratumumab treatment
• Standard systemic antiviral agents were not tolerated
• Ophthalmologic intervention was deemed critical for patient care

Abstract